To discuss the recent news from Exothera that the company are expand into North America, we at EPM caught up with Darren Leva, Chief Business Officer, Exothera.
EPM: Can you explain how Exothera's expansion of the Ntensify platform into North America will impact the development and manufacturing of RNA therapies in the region?
DL: Through our expansion into the US, developers of RNA therapeutics and vaccines will have access to the most advanced RNA production processes and equipment, allowing for fast delivery of therapeutics and vaccines to their patients on US soil.